Kuwait Obesity Research: Who Funds GLP-1s and What Payers Need to See — Obesity market research Kuwait: funding, tenders and evidence

Obesity market research Kuwait is a funding and access problem before it is a sizing problem. The Ministry of Health supplies medicines into a public system that is free for Kuwaiti nationals, while expatriates — about 70% of residents as of mid-2026 (PACI, via Arab Times) — face a different entitlement and a shorter branded-drug list (Awad et al., 2022). Brand, access and HEOR teams therefore need to know who pays for GLP-1s, which channel dispenses them, and what evidence public and private payers will ask for before they fund a weight-management indication. This briefing uses only published sources. It sits alongside our healthcare market research hub and our page on Kuwait obesity market insights.

Obesity market research Kuwait: who funds GLP-1s?

Three wallets fund a GLP-1 in Kuwait. They are not substitutes for each other, and a forecast that blends them will overstate one group and understate the other.

• The Ministry of Health public system. Public services are free for Kuwaiti nationals, GCC nationals, and expatriates who work for the Ministry of Health and their relatives (Awad et al., 2022). Alali and colleagues wrote in 2025 that GLP-1 receptor agonists “are also available in government healthcare facilities for free,” while shortages and long waits still send patients to private clinics. That is a supply statement, not a published brand-level formulary.
• Expatriate cover, including DHAMAN. Other expatriate residents have paid an annual fee for public outpatient care and for “dispensing most the drugs except for the new expensive branded drugs” (Awad et al., 2022). The same paper excluded non-Kuwaitis because “many branded drugs are for Kuwaitis only.” Health Assurance Hospitals Company (DHAMAN) is the public–private network set up in 2014 to provide insurance programmes and care for private-sector expatriates (DHAMAN). We did not find a published DHAMAN GLP-1 or obesity-drug formulary, so do not assume a weight-management indication is a covered benefit.
• Private clinics and self-pay. The Ministry of Health publishes a national drug price list (MOH prices). In August 2025 it cut listed prices on 544 products, including a 30% cut on tirzepatide (Mounjaro), a 37.3% cut on Wegovy and a 20.8% cut on Saxenda (Kuwait Times / KUNA). Those cuts confirm that the three brands sit in the pricing system. They do not say who is entitled to receive them at public expense.

Report publishers such as Grand View Research and 6Wresearch sell Kuwait or GCC obesity and weight-management sizing. Those reports can triangulate a category total. They cannot tell you which of the three wallets will pay for a weekly injection, or what a hospital pharmacy committee will ask for. That is the job of commissioned obesity market research in Kuwait.

Registration and supply sit in front of every wallet. The Drug Registration and Control Administration registers medicines before they can enter Kuwait (MOH DRUGCA). The Medical Stores Administration, established in 1983, stores, orders and distributes medicines for the Ministry of Health (Medical Stores Administration). Tender, practice and direct-order documents are issued through the Ministry’s procurement channel (Kuwait Government Online). A product that is registered but not bought into Central Medical Stores supply is, for volume purposes, a private-channel brand.

How common is obesity and diabetes in Kuwait?

Ask every provider which prevalence baseline it uses. The published numbers are close in headline and different in method.

The 2014 STEPS survey, run by the Ministry of Health with WHO and drawn from PACI civil-registration rolls, measured 3,589 Kuwaiti adults aged 18–69. Obesity was 40.3% (36.5% in men, 44.0% in women) and overweight 37%, so 77.3% of the measured sample was overweight or obese (Weiderpass et al., 2019; WHO STEPS 2014). That survey is Kuwaiti nationals only. It is the last nationally reported measured STEPS dataset on WHO’s Kuwait surveillance page.

WHO’s Global Health Observatory models measured height and weight for adults aged 18 and over. Our World in Data’s 2026 processing of that GHO series puts age-standardised adult obesity in Kuwait at 40.4% in 2024 (Our World in Data / WHO GHO; WHO GHO indicator). Nagi et al. used an earlier WHO 2016 figure — 41.4% overall, 33.3% in men and 45.6% in women — as the lagged exposure for their 2024 cost-of-illness model (Nagi et al., 2026). A 2023 micro-costing paper opened with the statement that “44% of Kuwait’s population live with obesity” (Al-Sabah et al., 2023). Those four figures are not a time series. They are four methods.

The addressable adult population is also split by nationality. PACI reported 5,098,539 residents on 30 June 2025, of whom 1,550,547 were Kuwaiti and 3,547,992 were not (KUNA / PACI). By the end of June 2026 PACI’s published update, as reported by Arab Times, was 5.31 million residents, 1.567 million Kuwaitis and 3.743 million expatriates (PACI, via Arab Times). Because entitlement follows nationality, a prevalence applied to the whole 5.31 million overstates the publicly funded pool and understates the self-pay and insured-expat pool.

Diabetes is the comorbidity that should sit in every GLP-1 brief. The IDF Diabetes Atlas 11th edition ranks Kuwait third globally on age-standardised diabetes prevalence in adults aged 20–79, at 25.6% in 2024 (IDF). In a 2018 sample of 1,182 Kuwaiti adults with diabetes, 15.4% were using a GLP-1 receptor agonist (Awad et al., 2022). That is a diabetes-clinic figure from before the current weight-management wave. It is not a 2026 obesity-prescribing share.

Childhood obesity is a separate research question. A school sample of 6,574 students aged 6–18, measured in 2012–13, found 30.5% obesity on the WHO cut-off (Elkum et al., 2016). Do not mix that paediatric rate into an adult GLP-1 forecast.

For the wider market structure — public hospitals, Dasman Diabetes Institute, and the private clinic channel — see Kuwait obesity market insights and the Kuwait healthcare market report.

What does the economic burden tell payers?

The paper that currently ranks for “obesity market research Kuwait” is not a vendor report. It is Nagi, Ahmed, Almari, Almalki and Elradi’s March 2026 PLOS One cost-of-illness study. One author lists Dhaman Co, Kuwait City, as an affiliation (Nagi et al., 2026). The study estimated 2024 costs from governmental and societal perspectives for adults aged 20 and over.

The headline numbers a payer will recognise:

• KWD 4.29 billion ($14.03 billion) from the societal perspective, and KWD 3.92 billion ($12.82 billion) from the governmental perspective — about 1.3 times the 2024 Ministry of Health budget of KWD 3.04 billion (Nagi et al., 2026).
• 91.33% of the total was direct medical cost. Indirect productivity losses were 7.78%. Direct non-medical costs were 0.88% (Nagi et al., 2026).
• Of the direct medical costs, only 0.79% — about KWD 31.10 million — was the treatment of obesity itself. The rest was comorbidities. Type 2 diabetes contributed about KWD 1.23 billion; non-alcoholic fatty liver about KWD 1.04 billion (Nagi et al., 2026).
• The authors put 2,471,876 people living with obesity in 2024 (from World Obesity Atlas projections) and assumed that only 2% receive formal obesity treatment. They then allocated that treated group using the Alali 2024 molecule mix: 37.2% Wegovy/semaglutide, 31.3% Saxenda/liraglutide, 27.8% Mounjaro/tirzepatide (Nagi et al., 2026).
• A 20% fall in obesity and comorbidity prevalence cut the modelled societal cost by 28% (Nagi et al., 2026, Table 4).

Al-Sabah and colleagues, writing from the public-payer perspective in 2023, surveyed 70 public-sector clinicians and eight hospital procurement staff. They estimated that a person with any single obesity-related comorbidity incurred KWD 1,748–4,205 a year in direct healthcare costs, with asthma, chronic kidney disease and type 2 diabetes each above KWD 3,500 (Al-Sabah et al., 2023). That paper did not cost obesity treatment itself. Nagi et al. filled that gap — and still found treatment of obesity to be less than one per cent of medical spend.

For a payer, the implication is specific. A budget-impact model that only prices the GLP-1 class, and ignores the KWD 1.23 billion diabetes line, answers the wrong question. What they need to see is the offset — or the absence of an offset — against comorbidities they already fund, under the restrictions they actually apply. That is primary research plus a Kuwait-specific budget-impact, not a GCC average. Our Kuwait market access research page covers the access side of that brief.

How do patients actually obtain GLP-1s?

Published patient evidence is still a single convenience survey. Between February and May 2024, Alali and colleagues recruited adults in Kuwait who had been prescribed a GLP-1 injection for weight loss, mainly through weight-loss clinics and social media. Of 545 respondents, 486 named a medicine. The analysed group was 89% women and 81% Kuwaiti; mean BMI was 29.3. Semaglutide (Ozempic or Wegovy) accounted for 37.2%, liraglutide (Saxenda or Victoza) 31.3% and tirzepatide (Mounjaro) 27.8% (Alali et al., 2025).

The same paper is the source for two access facts that brand teams keep asking about. First, the authors stated that one pre-filled Ozempic injection was then priced at KWD 35, and that GLP-1s were available free in government facilities, with shortages and waits driving private-clinic use (Alali et al., 2025). That KWD 35 figure is the authors’ 2025 statement; the August 2025 Ministry price cuts on Wegovy, Saxenda and tirzepatide mean current listed prices should be read from the Ministry list, not from that sentence (Kuwait Times / KUNA; MOH prices). Second, 220 of 468 analysed participants — 47% — had already stopped. Among those 220, side effects were the most common reason (35.5%), then reaching a goal (32.7%), then cost (23.2%). Cost was cited by 44% of tirzepatide stoppers and 9.9% of semaglutide stoppers (Alali et al., 2025, Table 5). The sample is not national, not specialty-stratified and not a persistence study. It is still the only published picture of why people in Kuwait stop.

Bariatric surgery remains the high-volume alternative that a GLP-1 brief has to sit beside. The Ministry of Health’s third National Bariatric Registry Report for 2023 recorded 6,484 cases from seven public hospitals (Al Adan, Al Amiri, Farwaniya, Jahra, Mubarak Al-Kabeer, Al Sabah and Jaber) and 102 surgeons: 5,270 primary procedures (81.3%), 874 revisions (13.5%) and 340 balloon insertions (5.2%) (Kuwait National Bariatric Registry 2023). A pharmacotherapy forecast that ignores that surgical base will misread both referral and combination use. See also obesity patient journey research in the GCC.

What should a Kuwait payer evidence pack include?

Payers in Kuwait are not one committee. A Ministry procurement official, a hospital pharmacy and therapeutics committee, a DHAMAN or private-insurer medical director, and a private-clinic owner each see a different cost. The public evidence above says they will ask for different things.

1. Indication and entitlement. Separate type 2 diabetes from weight management, and Kuwaiti nationals from expatriates. Awad et al. documented that many branded drugs are for Kuwaitis only.
2. Supply, not just registration. Show whether the product is registered (DRUGCA), priced (MOH prices) and actually bought into Central Medical Stores (Medical Stores Administration).
3. Budget impact against comorbidities already funded. Nagi et al. put obesity treatment at 0.79% of direct medical costs and type 2 diabetes at KWD 1.23 billion. A model that ignores that split will be sent back.
4. Persistence and discontinuation. The only published Kuwait weight-loss GLP-1 survey found that 47% had stopped, with cost a larger share of tirzepatide stops than of semaglutide stops.
5. Who may initiate. The Alali survey recruited from weight-loss clinics; Awad’s 2018 diabetes sample was hospital and primary-care diabetes clinics. A 2026 brief should recruit endocrinology, internal medicine, family medicine and bariatric surgery separately.
6. Public versus private channel economics. Free public supply with shortages, versus listed retail prices after the 2025 cuts, versus any insured-expat benefit.
7. Surgical alternative. 6,484 registry cases in 2023 is a real comparator, not a footnote.
8. Local language and local sites. Instruments in Arabic and English; respondents in Capital, Hawalli, Farwaniya and Ahmadi, not a Riyadh or Dubai proxy.

What should obesity market research Kuwait measure?

Design the study backwards from the decision. For a launch, a tender cycle or a restriction review, most briefs should cover:

• Prescriber segments. Endocrinology, internal medicine, family medicine and bariatric surgery, reported separately, in public hospitals and private clinics.
• Formulary and tender criteria. What hospital pharmacy committees and Central Medical Stores buyers actually score — clinical evidence, price, supply continuity, local-agent capability.
• Molecule and brand choice. Semaglutide, tirzepatide, liraglutide and any non-originator brands on the Ministry list, plus oral versus injectable where relevant.
• National versus expatriate pathways. Entitlement, out-of-pocket exposure, provider choice and persistence for each group. PACI’s mid-2026 split is about 30% Kuwaiti and 70% expatriate.
• Persistence drivers. Side effects, cost, goal attainment and supply interruptions, building on — not copying — the 2024 clinic/social-media sample.
• Payer evidence gaps. What MOH, hospital committees and insurers say they still need: budget impact, comorbidity offsets, restriction rules.
• Sizing baseline. State whether the model uses STEPS 2014 (Kuwaiti, measured), WHO GHO 2024 (modelled, all adults) or the World Obesity Atlas headcount Nagi used, and test the range.

For country context, compare obesity market research in Saudi Arabia, the UAE obesity market, Egypt obesity and GLP-1 research and GCC obesity market research. The Saudi buyer’s shortlist, who does obesity market research in Saudi Arabia, is a different question in a different reimbursement system — do not import its CHI or SFDA answers into Kuwait.

How should you commission the study?

• How many endocrinologists, internists, family physicians and bariatric surgeons will you recruit, and from which governorates?
• Will results be reported by nationality and by public versus private practice?
• Which prevalence baseline will you use, and why?
• Will the discussion guide ask about Ministry supply, DHAMAN or private insurance, and self-pay as three separate routes?
• Are questionnaires available in Arabic and English?
• Who owns the data, and can it be re-cut after a tender question changes?

Desk-research reports remain useful for a first cut of category size. Grand View Research and 6Wresearch publish Kuwait or GCC obesity and anti-obesity pages that often appear for this query. Use them to triangulate. Do not use them as the evidence pack you take to a Ministry or insurer meeting.

Why choose BioNixus for obesity market research in Kuwait?

BioNixus is a primary market research and market access consultancy for pharmaceutical, medical device and healthcare companies, founded in 2012. It has served 118 clients in 48 countries, has run 127 studies so far in 2026 and works with a network of about 3,200 physicians. Custom study pricing is typically $10k–$60k. Regional leadership offices are in Sheridan, Wyoming (US headquarters), London EC1V 2NX and Cairo (Sheikh Zayed, Giza). Dubai, Al Khobar and Salmiya, Kuwait (Olympia Mall) are field offices, and it is in the process of opening a São Paulo office by the end of 2026. LATAM work is covered from the US office with a strong local consultant network.

Choose BioNixus when the decision depends on why Kuwaiti and expatriate patients, public-hospital specialists and payers act as they do, rather than on a GCC category total. Each study is built around one decision — a tender, a restriction, a launch sequence — and is reported for brand, medical and access teams. The delivery commitment is Guaranteed in writing. That guarantee covers the agreed scope and timeline, not the accuracy of findings. Where reviews are relevant, BioNixus has 40 client reviews.

See also healthcare market research in Kuwait, pharmaceutical market research in Kuwait and top market research companies in Kuwait, and our global ranking of obesity market research firms.

To brief a Kuwait obesity or GLP-1 study, use the BioNixus contact form or email admin@bionixus.com.

References

1. World Health Organization. Global Health Observatory: Obesity among adults, BMI ≥ 30 kg/m² (age-standardized estimate), indicator NCD_BMI_30A; Kuwait 2024 value as published in the GHO / Our World in Data release processed from WHO GHO (2026). Source (accessed 12 October 2026).
2. Our World in Data, from World Health Organization – Global Health Observatory (2026). Obesity among adults, BMI ≥ 30 kg/m² (age-standardized estimate), adults 18+, both sexes, Kuwait 2024: 40.4%. Source (accessed 12 October 2026).
3. Weiderpass E, et al. The Prevalence of Overweight and Obesity in an Adult Kuwaiti Population in 2014. Front Endocrinol. 2019;10:449. doi:10.3389/fendo.2019.00449. Analysis of the 2014 WHO STEPS survey of Kuwaiti adults. Source (accessed 12 October 2026).
4. World Health Organization / Ministry of Health. Kuwait STEPS 2014 study description (adults 18–69). Source (accessed 12 October 2026).
5. Nagi MA, Ahmed H, Almari M, Almalki ZS, Elradi YMZ. A comprehensive economic assessment of the burden of obesity in Kuwait. PLoS One. 2026;21(3):e0344040. doi:10.1371/journal.pone.0344040. Source (accessed 12 October 2026).
6. Alali S, Al-Otaibi W, Ashodian N, Achour H, Almulla A, Mutlaq M. A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait. Front Nutr. 2025;12:1590379. doi:10.3389/fnut.2025.1590379. Source (accessed 12 October 2026).
7. Awad A, et al. Utilization and cost of drugs for diabetes and its comorbidities and complications in Kuwait. PLoS One. 2022;17(6):e0268495. doi:10.1371/journal.pone.0268495. Source (accessed 12 October 2026).
8. Al-Sabah S, ElShamy A, Jois S, Low K, Gras A, Gulnar EP. The economic impact of obesity in Kuwait: a micro-costing study evaluating the burden of obesity-related comorbidities. J Med Econ. 2023;26(1):1368–1376. doi:10.1080/13696998.2023.2265721. Source (accessed 12 October 2026).
9. International Diabetes Federation. IDF Diabetes Atlas, 11th edition. Chapter 3: The global picture of diabetes. Age-standardised diabetes prevalence in adults 20–79 years, 2024: Kuwait 25.6% (third globally). Source (accessed 12 October 2026).
10. Kuwait News Agency (KUNA). Kuwait PACI: population reaches 5,098,539 (as of 30 June 2025). 22 July 2025. Kuwaitis 1,550,547; non-Kuwaitis 3,547,992. Source (accessed 12 October 2026).
11. Arab Times, quoting the Public Authority for Civil Information (PACI). Expat boom lifts Kuwait population to 5.31 million by end of June 2026. Kuwaitis 1.567 million; expatriates 3.743 million. Source (accessed 12 October 2026).
12. Kuwait Times, citing KUNA. Kuwait cuts prices on 544 medicines, weight loss drugs. 11 August 2025. Tirzepatide (Mounjaro) −30%; Wegovy −37.3%; Saxenda −20.8%. Source (accessed 12 October 2026).
13. Ministry of Health, Kuwait. Drug Registration and Control Administration (DRUGCA): registration of medicines, herbal products, food supplements and medical devices. Source (accessed 12 October 2026).
14. Ministry of Health, Kuwait. Drug and food supplement prices (list updated March 2025). Source (accessed 12 October 2026).
15. Medical Stores Administration (Central Medical Stores), Ministry of Health, Kuwait. Established 1983 for storage, ordering and distribution of medicines. Source (accessed 12 October 2026).
16. Kuwait Government Online. Obtaining the documents of tenders, practices or direct orders from the Ministry of Health. Source (accessed 12 October 2026).
17. Health Assurance Hospitals Company (DHAMAN). About DHAMAN: public–private partnership healthcare organisation established in 2014 under New Kuwait 2035. Source (accessed 12 October 2026).
18. Dendrite Clinical Systems / Ministry of Health. 3rd Kuwait National Bariatric Registry Report 2023: 6,484 cases from seven public hospitals and 102 surgeons. Source (accessed 12 October 2026).
19. Elkum N, Al-Arouj M, Sharifi M, Shaltout A, Bennakhi A. Prevalence of childhood obesity in the state of Kuwait. Pediatr Obes. 2016;11(6):e30–e34. doi:10.1111/ijpo.12090. Measured 6,574 students aged 6–18 in 2012–13; WHO obesity 30.5%. Source (accessed 12 October 2026).
20. Grand View Research. Kuwait / GCC obesity and weight-management report pages that rank for obesity market research Kuwait. (accessed 12 October 2026).
21. 6Wresearch. Kuwait and GCC obesity treatment and anti-obesity drug report pages. (accessed 12 October 2026).